Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2005

01-10-2005 | Adis Drug Profile

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis

A Viewpoint by Nicole M.A. Blijlevens and Shaun McCann

Authors: Nicole M. A. Blijlevens, Shaun McCann

Published in: Drugs | Issue 15/2005

Login to get access

Excerpt

Oral mucositis is induced by the myelotoxic agents used to treat patients with haematological or nonhaematological malignancies to prepare them for haematopoietic stem cell transplantation (HSCT). Oral mucositis affects the patient’s health-related quality of life because the difficulty in eating and drinking often necessitates the administration of total parenteral nutrition. Intense pain is the most obvious and troublesome symptom requiring narcotic analgesia and the risk of infection can be life threatening. Hitherto, virtually all attempts to prevent or ameliorate mucositis with oral rinses, antimicrobial therapy and other remedies have failed. …
Literature
1.
2.
Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351(25): 2590–8PubMedCrossRef
Metadata
Title
Palifermin in Myelotoxic Therapy-Induced Oral Mucositis
A Viewpoint by Nicole M.A. Blijlevens and Shaun McCann
Authors
Nicole M. A. Blijlevens
Shaun McCann
Publication date
01-10-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565150-00010

Other articles of this Issue 15/2005

Drugs 15/2005 Go to the issue

Adis Drug Profile

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis

Current Opinion

How Important is Onset of Action in Ulcerative Colitis Therapy?

Adis Drug Evaluation

Infliximab

Adis Drug Profile

Lansoprazole in the Treatment of Gastrooesophageal Reflux Disease in Children and Adolescents

Leading Article

Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg)

Adis Drug Profile

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis